A 70-Year-Old Man with Early Relapsed/Refractory Multiple Myeloma
The panelist discusses how the patient had triplet therapy 6 years ago, which was the standard for myeloma treatment at the time. Since then, the patient has had a biochemical relapse, renal insufficiency, and moderate anemia, so he needs therapy but not immediate therapy.
Video content above is prompted by the following:
- Please share your initial impressions of the patient case.
- A decision to switch therapy was made. What regimen are you most likely to recommend for this patient?
- How do you set a patient up for the best success in early-stage R/R MM?
Recent Videos
Related Content
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Article
Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More
